Survey

How are the Trump tariffs affecting you? Take our survey and let us know.

Mexico - Delayed Quote MXN

Atossa Therapeutics, Inc. (ATOS.MX)

15.50

+2.50

+(19.23%)

At close: April 24 at 12:18:44 PM CST

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ATOS.MX

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

GNFT Genfit S.A.

3.6700

-2.65%

FBRX Forte Biosciences, Inc.

6.96

+15.04%

ENVB Enveric Biosciences, Inc.

1.3348

+3.47%

KALA KALA BIO, Inc.

3.3000

+5.77%

BLUE bluebird bio, Inc.

4.1600

+1.71%

PHIO Phio Pharmaceuticals Corp.

2.2300

+9.31%

CAPR Capricor Therapeutics, Inc.

13.28

+0.99%

VXRT Vaxart, Inc.

0.3600

+4.74%

INO Inovio Pharmaceuticals, Inc.

1.9200

+2.67%

PSTV Plus Therapeutics, Inc.

0.8427

-14.32%